Home > Insider Trading > Filing (0001209191-15-060844)

Filing Details

Accession Number:: 0001209191-15-060844
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-07-14 20:39:16
Reporting Period:: 2015-07-10

Filing Date:: 2015-07-14
Accepted Time:: 2015-07-14 20:39:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1328143	Adamas Pharmaceuticals Inc	ADMS	Pharmaceutical Preparations (2834)	421560076

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1027621	D Jonathan Feiber	3000 Sand Hill Road Suite 3-290 Menlo Park CA 94025	No	No	Yes	No
1129541	Mdv Vii Lp	C/O Mohr Davidow Ventures 3000 Sand Hill Road, Suite 3-290 Menlo Park CA 94025	No	No	Yes	No
1250354	J Nancy Schoendorf	3000 Sand Hill Road Suite 3-290 Menlo Park CA 94025	No	No	Yes	No
1410787	Mdv Ix Lp	C/O Mohr Davidow Ventures 3000 Sand Hill Road, Suite 3-290 Menlo Park CA 94025	No	No	Yes	No
1564546	Seventh Mdv Partners, L.l.c.	3000 Sand Hill Road Suite 3-290 Menlo Park CA 94025	No	No	Yes	No
1573991	Ninth Mdv Partners, L.l.c.	3000 Sand Hill Road Suite 3-290 Menlo Park CA 94025	No	No	Yes	No
1605837	Mdv Enf Vii (A), L.p.	3000 Sand Hill Road Suite 3-290 Menlo Park CA 94025	No	No	Yes	No
1605838	Mdv Enf Vii (B), L.p.	3000 Sand Hill Road Suite 3-290 Menlo Park CA 94025	No	No	Yes	No
1605840	Mdv Vii Leaders' Fund, L.p.	3000 Sand Hill Road Suite 3-290 Menlo Park CA 94025	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-07-10	8,657	$27.53	287,992	No	4	S	Indirect	MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,772,686	Indirect	MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP
Common Stock	265,150	Indirect	MDV VII, L.P.
Common Stock	6,043	Indirect	MDV ENF VII (A), L.P.
Common Stock	3,146	Indirect	MDV ENF VII (B), L.P.
Common Stock	25,661	Indirect	MDV VII Leaders' Fund, L.P.

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by MDV IX on December 15, 2014.
Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $27.50 and $27.68 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Ninth MDV Partners, L.L.C. is the general partner of MDV IX, L.P., as nominee for MDV IX, L.P. and MDV ENF IX, L.P. (collectively, "MDV IX"). William Ericson ("Ericson") and Jonathan Feiber ("Feiber") are Managing Members of Ninth MDV Partners, L.L.C. Ericson and Feiber may be deemed to share voting and dispositive power over the shares held by MDV IX. Each Reporting Person disclaims beneficial ownership of the shares held by MDV IX except to the extent of any pecuniary interest therein. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.
Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.